Results 51 to 60 of about 40,797 (259)

Incidence of deep vein thrombosis among non‐ICU patients hospitalized for COVID‐19 despite pharmacological thromboprophylaxis

Journal of Thrombosis and Haemostasis, 2020
A remarkably high incidence of venous thromboembolism (VTE) has been reported among critically ill patients with COVID‐19 assisted in the intensive care unit (ICU).
A. Santoliquido, Angelo Porfidia, A. Nesci, G. De Matteis, G. Marrone, E. Porceddu, Giulia Cammá, I. Giarretta, M. Fantoni, F. Landi, A. Gasbarrini, R. Pola, M. E. D’Alfonso, M. L. Lo Monaco   +13 more
semanticscholar   +1 more source

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis

Blood Advances, 2021
Background: COVID-19 related acute illness is associated with an increased risk of venous thromboembolism (VTE).
A. Cuker, E. Tseng, R. Nieuwlaat, P. Angchaisuksiri, C. Blair, Kathryn E. Dane, Jennifer Davila, M. Desancho, D. L. Diuguid, D. Griffin, S. Kahn, F. Klok, A. Lee, I. Neumann, A. Pai, M. Righini, Kristen M. Sanfilippo, D. Siegal, M. Skara, Deirdra R. Terrell, Kamshad Touri, E. Akl, Reyad Nayif Al Jabiri, Y. A. Al Jabiri, A. Barbara, Antonio Bognanni, Imad Bou Akl, M. Boulos, R. Brignardello-Petersen, R. Charide, M. Chan, L. Colunga-Lozano, K. Dearness, A. Darzi, H. Hussein, Samer G. Karam, Philipp Kolb, Razan Mansour, G. P. Morgano, R. Morsi, Giovanna E U Muti-Schünemann, Menatalla K Nadim, Atefeh Noori, Binu A Philip, Thomas Piggott, Yuan Qiu, Yetiani Roldan Benitez, Finn Schünemann, A. Stevens, K. Solo, W. Wiercioch, R. Mustafa, H. Schünemann   +52 more
semanticscholar   +1 more source

Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis [PDF]

, 2018
Background: Cancer-Associated thrombosis is common. Recommended treatment is daily injected low-molecular-weight heparin for 6months. Most studies focus on prophylaxis and treatment; few have explored patients’ experience.
Benelhaj, Naima B., Hutchinson, Ann, Ilyas, Muhammad Waqas, Johnson, Miriam J., Maraveyas, Anthony M., Seymour, Julie D.   +5 more
core   +1 more source

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients

Critical Care, 2020
Background A substantial proportion of critically ill COVID-19 patients develop thromboembolic complications, but it is unclear whether higher doses of thromboprophylaxis are associated with lower mortality rates. The purpose of the study was to evaluate
Sandra Jonmarker, J. Hollenberg, M. Dahlberg, O. Stackelberg, Jacob Litorell, Åsa H. Everhov, H. Järnbert-Pettersson, M. Söderberg, J. Grip, A. Schandl, Mattias Günther, M. Cronhjort   +11 more
semanticscholar   +1 more source

Thrombin generation in patients with COVID-19 with and without thromboprophylaxis

Clinical Chemistry and Laboratory Medicine, 2021
Objectives Thrombin generation (TG) with and without thrombomodulin (TM) was evaluated in COVID-19 patients with different disease severity and thromboprophylaxis regimen, in order to understand the prothrombotic profile.
E. Campello, C. Bulato, L. Spiezia, A. Boscolo, Francesco Poletto, M. Cola, S. Gavasso, C. Simion, C. Radu, A. Cattelan, I. Tiberio, R. Vettor, P. Navalesi, P. Simioni   +13 more
semanticscholar   +1 more source

Chemotherapy treatment of multiple myeloma patients increases circulating levels of endothelial microvesicles [PDF]

, 2016
Correspondenc
Adesanya, M. Adeola, Gardiner, Eric, Hall, Jessica, Madden, Leigh, Maraveyas, Anthony, Sayala, Haz   +5 more
core   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine, 2020
Background: Preliminary evidence indicates that prophylactic-dose thromboprophylaxis may be inadequate to control the increased risk of venous thromboembolism (VTE) in patients hospitalized for coronavirus disease 2019 (COVID-19) infection. Additionally,
G. Chi, Jane J Lee, Adeel Jamil, Vamsikrishna Gunnam, H. Najafi, Sahar Memar Montazerin, Fahimehalsadat Shojaei, Jolanta Marszalek   +7 more
semanticscholar   +1 more source

Short runs of atrial arrhythmia and stroke risk: a European-wide online survey among stroke physicians and cardiologists [PDF]

, 2016
Methods: An online survey of cardiologists and stroke physicians was carried out to assess current management of patients with short runs of atrial arrhythmia within Europe. Results: Respondents included 311 clinicians from 32 countries.
Abdul-Rahim, A.H., Lees, K.R., Lip, G.Y.H., Rankin, A.C., Rankin, A.J., Tran, R.T.   +5 more
core   +1 more source

MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy

Frontiers in Immunology, 2020
Numerous clinical trials of mesenchymal stromal/stem cells (MSCs) as a new treatment for coronavirus-induced disease (COVID-19) have been registered recently, most of them based on intravenous (IV) infusion.
Guido Moll, N. Drzeniek, Julian Kamhieh-Milz, S. Geissler, H. Volk, P. Reinke   +5 more
semanticscholar   +1 more source